Trial Profile

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacodynamic Markers, and Pharmacokinetics of AP-101 in Patients With Familial Amyotrophic Lateral Sclerosis (fALS) and Sporadic Amyotrophic Lateral Sclerosis (sALS)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Mar 2026 According to an AL-S Pharma media release, data from this study will be featured in an oral presentation at the AD/PD™ 2026 International Conference on Alzheimers and Parkinsons Diseases and related neurological disorders.
19 Mar 2026 Results presented in an AL-S Pharma Media Release.
07 Jan 2026 According to AL-S Pharma media release, data from the trial will be presented at the 44th Annual J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026, at 8:30 a.m. PT.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com